In the US market, in the event of a positive decision of the regulator, two new drugs for the treatment of migraine may appear at once: erenumab, jointly developed by Novartis and Amgen, and the drug freemanezumab, created by Teva Pharmaceuticals.

The drugs are a monoclonal antibody specific for the gene calcitonin peptide receptor (CGRP). Previous studies have shown that many migraine patients have elevated levels.. Blocking this peptide helps reduce the severity and frequency of migraine attacks.. Articles on the results of the third phase of trials of both drugs are published in the New England Journal of Medicine, according to the online publication for girls and women from 14 to 35 years old Pannochka. net Erenumab trials included 955 patients. 317 people received 70 mg of the drug per month, 319 patients received 140 mg per month, a control group of 319 people took placebo. The study lasted six months.. Before the start of the study, migraine " In the first group, who took 70 mg per month, this amount fell by 3.2 days, in the second - by 3.7 days.. In the placebo group, it decreased by 1.8 days. 43.3% of participants from the first group and 50% from the second managed to reduce the number of “lost” days by half or more.. Among those taking placebo, 26.6% of patients achieved this result.. Erenumab research continues, scientists plan to find out how long the effect of the drug lasts.

1130 people enrolled in final phase of fremanezumab study. They were divided into three roughly equal groups.. Members of the first group at the beginning of the first, fourth and eighth weeks were administered fremanezumab (first 675 mg, then 225 mg). Patients from the second group received 675 mg of the drug at the beginning of the first week, and then twice - a placebo.. People in the third group received only injections of a placebo - saline solution..

Initially, the frequency of headaches in all groups was 12–13 days per month.. In the first group, it decreased by an average of 4.6 days, in the second - by 4.3 days, and in those who took placebo - by 2.5 days. In 40% of patients treated with fremanezumab, the frequency of migraine attacks was halved or even more.. No pronounced side effects, in particular the effect on the liver, were found in the new drug..

According to the World Health Organization, up to 300 million people worldwide suffer from chronic migraine.. It causes attacks of severe headache up to 15 times a month for at least three months..

Among the symptoms of the disease are not only a throbbing headache, but also nausea, vomiting, increased sensitivity to light, sounds and smells.. A third of migraine sufferers have an aura, a complex of symptoms associated with blurred vision, dizziness, and hallucinations.. Despite the significant prevalence of the disease, there is no cure for it.. Available methods can only slightly reduce pain, but they are not able to save a person from it or prevent attacks..

aspect. net.